2003-2004 Grant Cycle : Research Grants Awarded
Biology of Breast Cancer
Characterizing Determinants of Tamoxifen Resistance in Human Breast Cancer: Role of CtIP (RBBP8)
C. Marcelo Aldaz, PhD
University of Texas M.D. Anderson Cancer Center
$250,000
Stromal Caveolin-1 Regulation of Breast Cancer Growth and Metastasis.
Robin Anderson, PhD
Peter MacCallum Cancer Centre
$250,000
Epigenetic Consequences of BRCA1: The Key to its Role as a Tumor Suppressor Gene in Human Breast Cancer
Bradley Arrick, MD
Trustees of Dartmouth College
$250,000
Mouse Models of Breast Cancer Based on Epigenetic Silencing of the Hic-1 and AP-2Ą Genes
Stephen Baylin, MD
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
$250,000
Epithelial Dependence on the Vasculature
Laura Benjamin, PhD
Beth Israel Deaconess Medical Center
$250,000
BP1, a New Homeobox Gene: a Strong Potential Target for Therapy of Breast Cancer
Patricia Berg, PhD
George Washington University Medical Center
$249,850
Role of the Heparin-Binding Growth Factor, Pleiotrophin, in Breast Cancer Motility and Invasion
Emma Bowden, PhD
Georgetown University
$250,000
Ceramide Metabolism As Prognostic Marker Of Chemotherapy Responsiveness And Metastatic Potential In Breast Cancer
Myles Cabot, PhD
John Wayne Cancer Institute
$250,000
CBFA2T3 is a Novel Breast Cancer Tumour Suppressor Gene: Investigation as a Prognostic Marker and Development of Drug Targets.
David Callen, PhD
University of Adelaide
$250,000
Preclinical Models for Treatment of Residual Neoplastic Disease
Lewis Chodosh, MD
University of Pennsylvania School of Medicine
$249,777
Progesterone Receptors and Hormonal Prevention of Breast Cancer
Orla Conneely, PhD
Baylor College of Medicine
$250,000
Fibroblast Activation Protein-Alpha Activation of a Bacterial Toxin as Targeted “Anti-Stromal” Therapy for Breast Cancer
Samuel Denmeade, MD
The Johns Hopkins School of Medicine
$250,000
Defining the Role of the Ras Family RERG Protein in Breast Cancer
Channing Der, PhD
University of North Carolina at Chapel Hill
$249,408
The Role of Toll-Like Receptors in Breast Cancer
Joseph DiDonato, PhD
Cleveland Clinic Foundation
$250,000
Mechanism of BCAR1/p130Cas-Mediated Estrogen-Independent Proliferation of Breast Cancer Cells
Lambert Dorssers, PhD
Josephine Nefkens Institute, Erasmus MC
$250,000
SWI/SNF: Mediator of the ER+/PR-, Tamoxifen-Resistant Phenotype?
Dorraya El-Ashry, PhD
The Regents of the University of Michigan for
$249,657
Identification of Novel Genetic Factors Contributing to Clinical Phenotypes in Large Families with BRCA1 and BRCA2 Mutations
Rachel Ellsworth, PhD
Windber Research Institute
$241,284
Syndecan-1 in Stromal Fibroblasts of Breast Carcinomas
Andreas Friedl, MD
University of Wisconsin-Madison
$250,000
Regulation of Breast Cancer Metastasis by Slit
Ramesh Ganju, PhD
Beth Israel Deaconess Medical Center
$250,000
The Role of RASSF1A in Cell Cycle Control After DNA Damage
Boning Gao, PhD
University of Texas Southwestern Medical Center at Dallas
$250,000
Does BRCA2 Justify Prophylactic Mastectomy? Allele-Specific Methylation Markers of BRCA2 v. AS3 Losses in Breast Cancer
Peter Geck, MD
Tufts University School of Medicine
$250,000
Identification of Metastasis Associated Breast Cancer Genes Using a High-Resolution Whole Genome Approach
Joseph Geradts, MD
Duke University
$250,000
Characterization of Chromosomal Condensation Defects in Breast Cancer
Henry Heng, PhD
Wayne State University
$250,000
Identification of Collaborating Mutations in Brca1 and Brca2 Mouse Mammary Tumors by Genome-Wide Screening for Chromosomal Imbalances
Jos Jonkers, PhD
Netherlands Cancer Institute
$250,000
Prevention of Genome Instability in Breast Cancer by Dietary Antimutagens
Catherine Klein, PhD
NYU School of Medicine
$199,859
Stop Breast Cancer with 3-BrPA, a Recently Discovered Anti-Metabolite with Strong Inhibiting Activity Against Primary and Metastatic Liver Cancer.
Young Ko, PhD
Johns Hopkins University
$250,000
The Role of the Stroma in Carcinogenesis
Maricel Maffini, PhD
Tufts University School of Medicine
$250,000
Molecular Mechanisms and Therapeutic Implications of a Novel Bi-Directional Cross-Talk Between the Lipogenic Enzyme Fatty Acid Synthase (FAS) and the HER-2/neu Oncogene in Breast Cancer
Javier Menendez, PhD
Fundacio Privada D'Investigacio Biomedica de Girona
$250,000
Disruption of Breast Cancer Chemoresistance by the Translational Antagonist 4E-BP1: A Bitransgenic Mouse Model
Vitaly Polunovsky, PhD
University of Minnesota
$250,000
Earlier Detection of Primary and Recurrent Breast Cancer Using Autoantibodies
John Robertson, MD
The University of Nottingham
$249,610
A Murine Model of Breast Cancer-Associated Lymphedema: Genome-Wide Transcriptional Profiling for the Study of Lymphedema Pathobiology, Cellular Signaling Mechanisms and Mechanisms of Therapeutic Lymphangiogenesis
Stanley Rockson, MD
Stanford University School of Medicine
$249,879
Role of Progestins and Progesterone Receptors in Hormone-Dependent Human Breast Cancers
Carol Sartorius, PhD
University of Colorado Health Sciences Center
$250,000
Determining the Role of CD44 in Breast Cancer Metastasis To the Lung
Joyce Schroeder, PhD
University of Arizona
$250,000
BRMS1 Regulates Osteopontin Expression in Metastatic Breast Cancer
Lalita Shevde-Samant, PhD
University of South Alabama
$250,000
Directed Delivery of RNA Interference Strategies to Breast Malignancies
Ernest Terwilliger, PhD
Beth Israel Deaconess Medical Center
$250,000
The Cellular Basis of Pregnancy-Mediated Protection Against Breast Cancer
Kay-Uwe Wagner, PhD
University of Nebraska Medical Center
$225,186
Molecular Mechanism of Estrogen Antagonists induced Suppression of Breast Cancer
Sheng Wang, PhD
Boston University School of Medicine
$249,810
Origins of Mammary Tumor Stromal Cells
Robert Weinberg, PhD
Whitehead Institute for Biomedical Research
$250,000
Role of Retinoid X Receptor and its Ligand in Breast Cancer
Xiao-kun Zhang, PhD
The Burnham Institute
$249,253
Early Detections, Diagnosis, and Prognosis
Nipple Aspirate Fluid Basic Fibroblast Growth Factor
Mai Nguyen Brooks, MD
UCLA
$250,000
JAB1-Mediated p27Kip1 Degradation as a Prognostic Factor and a Therapeutics Target for Breast Cancer
Francois Claret, PhD
M.D. Anderson Cancer Center
$250,000
Shc Signaling Proteins: Prognostic and Predictive Markers in Breast Cancer
A. Raymond Frackelton, PhD
Roger Williams Hospital
$250,000
Clinical Utility of Hypermethylated Genes in Primary Tumors and Body Fluids as Prognostic Markers of Breast Cancer Patients
Dave Hoon, PhD
John Wayne Cancer Institute
$250,000
Phosphopeptide Antibodies as Prognostic Indicators for Breast Cancer
Andrew Laudano, PhD
University of New Hampshire
$246,000
DNA Methylation Profiles for Diagnosis, Monitoring and Residual Disease Detection in Breast Cancer
Victor Levenson, MD
Northwestern University
$250,000
Prediction of Breast Cancer Outcome to Adjuvant Chemotherapy Using Expression Profiling
Dennis Sgroi, MD
Massachusetts General Hospital
$249,999
Computed Tomographic Prediction of Response to Treatment in Breast Cancer Induced Bone Metstasis
Brian Snyder, MD
Orthopedic Biomechanics Laboratory
$250,000
Etiology
Genetic Basis of DNA Repair Deficiency in Sporadic Breast Cancer
Stephen Grant, PhD
University of Pittsburgh
$249,498
Role of Nitrites/Nitrates in the Etiology of Breast Cancer
Mary Beth Martin, PhD
Georgetown University
$200,000
Characterization of Immunosuppressive Properties Induced by Eukaryotic Vector-Mediated Expression of HERV Genes Derived from Human Breast Cancer Cells
Feng Wang-Johanning, MD
UT MD Anderson Cancer Center
$249,936
Prevention
Molecular Targets of Breast Cancer Prevention by n-3 PUFAs
Huseyin Aktas, DVM
Harvard Medical School
$250,000
Role of Aromatase and COX-2 Inhibition in the Prevention of p53-Mediated Breast Cancer
Richard Arenas, MD
Baystate Medical Center
$249,991
A Novel Combinatorial Approach to Inhibit the Development of Mammary Cancer
Sarma Dittakavi, PhD
University of Toronto
$249,858
Anticancer and Chemopreventive Potential of Constituents of Black Cohosh on Breast Cancer
Linda Einbond, PhD
Columbia University College of Physicians and Surgeons
$250,000
Type-I and Type-II Anti-Tumor-Promotion Agents: Combinations of Tamoxifen, a New Retinoid, and Moderate Dietary Restriction in the Prevention of Experimental Breast Cancers
Isao Eto, PhD
The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham
$224,210
Lipocortin/Annexin I as a Unique Target of Mechanism-Based Chemoprevention of Breast Cancer
Fusao Hirata, MD
Wayne State University
$250,000
Inhibition of the Breast Cancer Marker MUC1 by the Chemopreventative, Indole-3-Carbinol
Insong Lee, PhD
University of Maryland
$249,555
Optical Transillumination Spectroscopy For Monitoring Breast Cancer Risk Changes
Lothar Lilge, PhD
University Health Network
$245,000
Delivery of Recombinant Mucin 1(MUC1) Protein and MUC1 Cytotoxic T Cell Epitopes into the Cytoplasm of Antigen Presenting Cells Using a Membrane Permeable Peptide for the Immunotherapy of Breast Cancer
Geoffrey Pietersz, PhD
Burnet Institute
$158,500
Does RARbeta2 P2 Methylation Predict Short-Term Breast Cancer Risk?
Victoria Seewaldt, MD
Duke University
$250,000
Monitoring the Effectiveness of NSAIDs Chemoprevention in Breast Cancer Using the CD13/APN Cell Surface Peptidase
Linda Shapiro, PhD
University of Connecticut Health Center
$250,000
Targeting DNA polymerase ß and Base Excision Repair in Breast Cancer: Characterization of a Novel p53-Independent Anti-Tumor Response
Robert Sobol, PhD
University of Pittsburgh Cancer Institute
$250,000
Green Tea Intervention for Weight Gain Prevention among Women with Breast Cancer
Cynthia Thomson, PhD
University of Arizona
$246,796
Effects of Soy on Estrogen Insuficency-induced Tamoxifen-Nonresponsive Breast Cancer
Jin-Rong Zhou, PhD
Beth Israel Deaconess Medical Center
$241,348
Treatment
A Novel Combination Approach of Anti-Her2/Neu and Anti-Prolactin for Breast Cancer
Wen Chen, PhD
Clemson University
$250,000
Genomic Consequences of Restoring p53 Transactivating Function with PRIMA-1 in Breast Cancer
Sayed Daoud, PhD
Washington State University
$250,000
Comparing a Plant Based Olive Oil Diet to a Conventional Diet in Women Diagnosed with Invasive Breast Cancer After the Age of 50 for Improvement in Biomarkers and Weight Loss
Mary Flynn, PhD
The Miriam Hospital, Providence, RI
$248,772
Radiosurgical Irradiation of the Tumor Bed for Early Stage Breast Cancers
Lijun Ma, PhD
UCSF Long Hospital
$250,000
A Novel Antiangiogenic and Antimetastatic Agent for Breast Cancer
Francis Markland, PhD
USC Keck School of Medicine
$250,000
Novel Breast Cancer Therapeutic Vectors Based on a Paramyxovirus Fusion Protein
Griffith Parks, PhD
Wake Forest University Health Sciences
$201,755
Inhibition of Breast Cancer Growth by a Novel Regulator of EGFR
Arun Rishi, PhD
Karmanos Cancer Institute, Wayne State University
$250,000
Immunogene Therapy of Breast Cancer
Mark Smyth, PhD
Peter MacCallum Cancer Centre
$250,000
Development of a Conditionally Replicative Adenovirus Targeted to HER-2/Neu-overexpressing Breast Cancer Through an Antisense Iron-responsive Element
Shao-Chun Wang, PhD
M. D. Anderson Cancer Center
$250,000
Overcoming Apoptosis-Resistance by Bcl-2/Bcl-xL-Bispecific Small Molecule Inhibitors as a Novel and Molecular Targeted Therapy for Breast Cancer
Liang Xu, MD
University of Michigan Medical School
$249,999
* Pending executed agreement
